LAB insider holdings triple after fresh RSU and option grants

Rhea-AI Filing Summary

Standard BioTools (NASDAQ:LAB) filed a Form 4 disclosing equity awards to director Kathy L. Hibbs executed on 20 Jun 2025.

The filing reports the grant of 94,592 restricted stock units (RSUs) that vest in full on 20 Jun 2026 or one day before the next annual shareholders’ meeting, contingent on continued service. Following the award, Hibbs’ direct ownership increased to 137,720 common shares.

In addition, Hibbs received a stock option for 125,660 shares exercisable at $1.05 per share. The option vests in twelve equal monthly instalments starting 20 Jul 2025 and expires 20 Jun 2035.

No shares were sold; all reported transactions were acquisitions recorded under direct ownership. The activity appears to reflect routine director compensation rather than open-market buying.

Positive

• Director Hibbs received 94,592 RSUs, lifting her direct ownership to 137,720 shares
• Award of 125,660 stock options at a modest $1.05 strike strengthens long-term alignment

Negative

• None.

Insights

Insider Transaction Analyst

TL;DR: Routine compensation grant—neutral signal

The RSU and option awards materially boost Hibbs’ stake, but because they are standard board compensation with no cash outlay, the market significance is limited. The one-year RSU cliff and 10-year option term align incentives yet do not suggest incremental insider conviction or urgency. Absent any sales, governance risk remains low. Overall, the disclosure is informational rather than market-moving.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HIBBS KATHY L

(Last) (First) (Middle)

C/O STANDARD BIOTOOLS INC.

2 TOWER PLACE, STE 2000

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
STANDARD BIOTOOLS INC. [ LAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/20/2025		A		94,592(1)	A	$0	137,720	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	$1.05	06/20/2025		A		125,660		(2)	06/20/2035	Common Stock	125,660	$0	125,660	D

Explanation of Responses:

1. Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 20, 2026 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.

2. The Option becomes exercisable in twelve equal monthly installments beginning on July 20, 2025, subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ Kathy L. Hibbs by Tomone Tanaka, Attorney-in-Fact	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Standard BioTools (LAB) RSUs were granted to director Kathy L. Hibbs on June 20, 2025?

The filing shows a grant of 94,592 restricted stock units to Kathy L. Hibbs.

What is the exercise price and vesting schedule of the new LAB options granted to Kathy L. Hibbs?

The option covers 125,660 shares at an exercise price of $1.05, vesting in 12 equal monthly instalments beginning July 20, 2025.

How many LAB shares does Kathy L. Hibbs own after the June 2025 transactions?

She now beneficially owns 137,720 common shares directly.

When will the RSUs granted to Kathy L. Hibbs fully vest?

The RSUs vest on 20 Jun 2026 or one day prior to the next annual shareholders’ meeting, whichever comes first, subject to continued service.

Did the Form 4 report any sale of LAB shares by Kathy L. Hibbs?

No. The filing reports only acquisitions; no shares were sold.